Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Product: Leveraxo
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Leveraxo 10mg modified-release tablets
0407020ADBPABAF
|
Leveraxo | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Leveraxo 20mg modified-release tablets
0407020ADBPACAG
|
Leveraxo | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Leveraxo 30mg modified-release tablets
0407020ADBPADAR
|
Leveraxo | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Leveraxo 40mg modified-release tablets
0407020ADBPAEAH
|
Leveraxo | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Leveraxo 5mg modified-release tablets
0407020ADBPAAAK
|
Leveraxo | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Leveraxo 60mg modified-release tablets
0407020ADBPAFAQ
|
Leveraxo | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Leveraxo 80mg modified-release tablets
0407020ADBPAGAI
|
Leveraxo | Oxycodone hydrochloride | Central Nervous System | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.